NA
KRTX

Neuburgh Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Neuburgh Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$205K Sell
12,584
-660
-5% -$12.8K 0.01% 670
2019
Q2 		$212K Buy
+13,244
New +$265K 0.01% 678

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuburgh Advisers's KRTX Position: Q3 2019 in Review

Neuburgh Advisers reduced its Karuna Therapeutics, Inc. Common Stock (KRTX) stake by 5% in Q3 2019, selling an estimated $12.8K and leaving 12,584 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #670.

Neuburgh Advisers first reported a position in KRTX in Q2 2019 and has held it in 2 quarters since. The position peaked at $212K in Q2 2019. 50 funds tracked by Wall St. Rank hold KRTX as of Q3 2019.

  • Neuburgh Advisers held 12,584 shares of Karuna Therapeutics, Inc. Common Stock worth $205K as of Q3 2019.
  • Neuburgh Advisers sold 660 Karuna Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $12.8K.
  • Karuna Therapeutics, Inc. Common Stock made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #670 holding.
  • Neuburgh Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 2 quarters since.
  • Neuburgh Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $212K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.